Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?Zacks Investment Research • 06/03/25
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic MelanomaGlobeNewsWire • 05/31/25
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual MeetingGlobeNewsWire • 04/23/25
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/07/25
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAMEGlobeNewsWire • 11/18/24
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAMEGlobeNewsWire • 11/08/24
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/05/24
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 TrialGlobeNewsWire • 10/10/24
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024GlobeNewsWire • 10/04/24
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development UpdateGlobeNewsWire • 09/16/24
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024GlobeNewsWire • 09/06/24
Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should KnowZacks Investment Research • 07/22/24
Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)Zacks Investment Research • 07/22/24